Building or investing in the anti-obesity drugs market?

The anti-obesity drug market is red hot right now, and the fight is moving from shots to pills.

We've found a lot of interesting signals. For example, Pfizer closed its purchase of Metsera, worth up to $10B, in November 2025, after a bidding war with Novo Nordisk. Then the FDA approved the first two obesity pills: Wegovy in December 2025, and Lilly's Foundayo in April 2026. Big drugmakers are paying billions to get in, and the leaders are racing to make treatment easier to take.

In this section, we look at why the market is shifting now, what pills and lower prices mean for demand, and where newcomers can still find room.

Obesity drives heart disease, diabetes and joint problems, yet most people who could benefit from these drugs still don't take them.

We look at six types of companies, from incretin drug makers and oral pill developers to amylin, muscle-preserving and brain-targeting programs. Those who pay include employers, insurers, government programs and patients paying cash. For each, we rank the biggest pains, like high prices, side effects that make people stop, muscle loss and factories that have to keep up with demand.

This shows which problems payers and patients will pay to solve, and why a new drug needs more than a bit more weight loss to stand out.

Obesity drug companies make money through prices paid by insurers, cash sales straight to patients, deals with governments, and licensing a promising drug to a bigger partner.

We compare who pays and what it costs to serve them. Insurers want lower net prices and proof of fewer heart attacks or less diabetes. Cash sales through company websites skip the middlemen, but at lower prices. Small-molecule pills can be cheaper to make at scale than peptide shots. And a biotech that licenses its drug gets cash early but gives up most of the upside.

You'll see which models still make good money as prices fall, and which depend on insurers who may stop paying.

Our growth numbers depend on a few forces that need to keep working. We take them one at a time.

Some drivers are plain to see: more people living with obesity, pills that are easier to take than shots, and lower prices. Others build on each other. Each trial that shows fewer heart or kidney problems makes insurers more willing to pay. More coverage brings more patients. And more patients justify bigger factories, which help bring prices down again.

Before building or investing, you should know what keeps patients on these drugs for years, and who will keep paying for them.

Novo Nordisk and Eli Lilly hold most of this market today, but dozens of companies are trying to take a share.

Some of the most interesting players work on narrow problems. Some try to protect muscle while patients lose fat. Others develop monthly shots, pills that are simpler to manufacture, or drugs that help people keep the weight off after they stop. Several license drugs first discovered in China.

They're hard to compare because their trials differ. Studies run for different lengths, in different patients, at different doses, so a headline weight-loss number rarely tells the full story.

Below, you'll find the market grids and ecosystem maps we've built to show who works on which mechanism, and where new players are getting in.

Zealand Pharma, Viking Therapeutics, Structure Therapeutics… a few challengers are getting closer to the leaders. None has an obesity drug on the market yet.

Their routes differ. Zealand Pharma teamed up with Roche to take its amylin drug, petrelintide, into phase 3. Viking Therapeutics is running its own phase 3 trials of an injectable drug, VK2735. Structure Therapeutics is developing a small-molecule pill and preparing it for phase 3. Each picked a different way to stand out, and none has proven it yet.

We'll look at how these companies chose their edge, found money for very large trials, and decided whether to partner or go alone.